Darolutamide significantly improved metastasis-free survival versus placebo in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.
Original Article: Darolutamide Improves MFS in Phase III Nonmetastatic CRPC Trial